# US 2022/0031840 A1 · Method of Treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031840 A1
- Document ID: US20220031840A1
- Status: Published application
- Kind: A1
- Application number: 17/309,499
- Filed: 2019-12-03
- Published: 2022-02-03
- Earliest claimed: 2018-12-03
- Assignees: HaemaLogix Pty Ltd
- Applicants: HaemaLogix Pty Ltd
- Inventors: Rosanne Dunn; Ben R. Herbert; Edmond J. Breen
- Web page: https://patentgrep.com/patent/US20220031840A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 31/69: Boron compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/3061: {Blood cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to therapeutic combinations comprising an anti-KMA antibody and a proteasome inhibitor for the treatment of multiple myeloma. The present disclosure also relates to methods of treating multiple myeloma in subjects with high serum cytokine levels.

## Claims

### Claim 1

A method of treating multiple myeloma in a subject in need thereof, the method comprising administering to the subject an anti-KMA antibody and a proteasome inhibitor.

### Claim 2

A therapeutic combination comprising a proteasome inhibitor and an anti-KMA antibody, the combination being provided for simultaneous or sequential administration.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or the therapeutic combination according to claim 2, wherein the proteasome inhibitor is selected from the group consisting of marizomib, oprozomib, epoxomicin, salinosporamide A, carfilzomib, ixazomib and bortezomib.

### Claim 4 (depends on 3)

The method or therapeutic combination according to claim 3, wherein the proteasome inhibitor is bortezomib.

### Claim 5 (depends on 1, 2, 3, 4)

The method or therapeutic combination according to any one of claims 1 to 4, wherein the anti-KMA antibody binds to or specifically binds to an epitope of KMA that is specifically bound by kappamab or that competes with kappamab for binding to KMA, wherein kappamab has a heavy chain variable region (VH) comprising a sequence set forth in SEQ ID NO: 1 and a light chain variable region (VL) comprising a sequence set forth in SEQ ID NO: 2.

### Claim 6 (depends on 5)

The method or therapeutic combination according to claim 5, wherein the epitope of KMA comprises a sequence set forth in SEQ ID NO: 5.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method or therapeutic combination according to any one of claims 1 to 6, wherein the anti-KMA antibody comprises a VH and a VL, the VH comprising a complementarity determining region (CDR) 1 comprising an amino acid sequence as shown in SEQ ID NO: 6, a CDR2 comprising an amino acid sequence as shown in SEQ ID NO: 7 and a CDR3 comprising a sequence as shown in SEQ ID NO: 8 and the VL comprising a CDR 1 comprising an amino acid sequence as shown in SEQ ID NO: 9, a CDR2 comprising an amino acid sequence as shown in SEQ ID NO: 10 and a CDR3 comprising a sequence as shown in SEQ ID NO: 11.

### Claim 8 (depends on 7)

The method or therapeutic combination according to claim 7, wherein the VH comprises an amino acid sequence at least about 95% identical to the amino acid sequence shown in SEQ ID NO: 1.

### Claim 9 (depends on 7, 8)

The method or therapeutic combination according to claim 7 or 8, wherein the VL comprises an amino acid sequence at least about 95% identical to the amino acid sequence shown in SEQ ID NO: 2.

### Claim 10 (depends on 7, 9)

The method or therapeutic combination according to claim 7 or 9 wherein the VH comprises an amino acid sequence as shown in SEQ ID NO: 1.

### Claim 11 (depends on 7, 8)

The method or therapeutic combination according to any one of claim 7 or 8, wherein the VL comprises an amino acid sequence as shown in SEQ ID NO: 2.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6)

The method or therapeutic combination according to any one of claims 1 to 6, wherein the VH comprises an amino acid sequence as shown in SEQ ID NO: 1 and the VL comprises an amino acid sequence as shown in SEQ ID NO: 2.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method according to any one of claims 1 to 12, wherein the anti-KMA antibody is administered at a dosage ranging from about 0.3 mg/kg to 30 mg/kg.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method according to any one of claims 1 to 12, wherein the anti-KMA antibody is administered at a dosage ranging from about 1 mg/kg to 10 mg/kg.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method according to any one of claims 1 to 12, wherein the anti-KMA antibody is administered at about 10 mg/kg.

### Claim 16 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method according to any one of claims 4 to 15, wherein the proteasome inhibitor is administered at a dose ranging from about 0.5 mg/m2 to about 1.5 mg/m2.

### Claim 17 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method according to any one of claim 1 or 3 to 15, further comprising administering one or more additional anti-cancer agents.

### Claim 18 (depends on 2)

The therapeutic combination according to claim 2, further comprising one or more additional anti-cancer agents.

### Claim 19 (depends on 17, 18)

The method according to claim 17 or the therapeutic combination according to claim 18, wherein the one or more additional anti-cancer agent(s) is/are selected from the group consisting of a chemotherapy, an immunomodulatory drug (thalidomide, lenalidomide, pomalidomide), a histone deacetylase inhibitor (panobinostat), an antibody (elotuzumab, daratumumab, isatuximab), a steroid (dexamethasone).

### Claim 20 (depends on 17, 19)

The method according to claim 17 or the therapeutic combination according to claim 19, wherein the additional anti-cancer agent is dexamethasone.

### Claim 21 (depends on 17, 19)

The method according to claim 17 or the therapeutic combination according to claim 19, wherein the additional anti-cancer agents are dexamethasone and lenalidomide.

### Claim 22 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21)

The method according to any one of claim 1 or 3 to 17 or 19 to 21, wherein the anti-KMA antibody and proteasome inhibitor are administered simultaneously or sequentially.

### Claim 23 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22)

The method according to any one of claim 1 or 3 to 17 or 19 to 22, wherein the anti-KMA antibody is administered monthly.

### Claim 24 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 22)

The method according to any one of claim 1 or 3 to 17, 19 or 22, wherein the subject has received at least one, at least two, at least three, at least four, at least five, at least six prior lines of therapy.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the subject achieved at least a minimal response (25% reduction in M protein) to their most recent line of therapy.

### Claim 26 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25)

The method according to any one of claim 1 or 3 to 17 or 19 to 25, wherein the subject is refractory to at least one, at least two, at least three, at least four prior lines of therapy.

### Claim 27 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26)

The method according to any one of claim 1 or 3 to 17 or 19 to 26, wherein the subject is refractory to at least one proteasome inhibitor.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the subject is refractory to bortezomib.

### Claim 29 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method according to any one of claim 1 or 3 to 17 or 19 to 28, wherein the subject has relapsed myeloma.

### Claim 30 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method according to any one of claim 1 or 3 to 17 or 19 to 28, wherein the subjects multiple myeloma has relapsed and is refractory to at least one proteasome inhibitor.

### Claim 31 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method according to any one of claim 1 or 3 to 17 or 19 to 30, wherein the serum level of kappa free light chain in a sample obtained from the subject is less than about 250 mg/ml.

### Claim 32 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claim 1 or 3 to 17 or 19 to 31, wherein the serum level of HGF in a sample obtained from the subject is between about 0.18 ng/ml and 1.6 ng/ml.

### Claim 33 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claim 1 or 3 to 17 or 19 to 31, wherein the serum level of MIF in a sample obtained from the subject is between about 414 pg/ml and 4707 pg/ml.

### Claim 34 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claim 1 or 3 to 17 or 19 to 31, wherein the serum level of CCL27 in a sample obtained from the subject is between about 150 pg/ml and 600 pg/ml.

### Claim 35 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claim 1 or 3 to 17 or 19 to 31, wherein the serum level of G-CSF in a sample obtained from the subject is between about 20 pg/ml and 65 pg/ml.

### Claim 36 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claim 1 or 3 to 17 or 19 to 31, wherein the serum level of CXCL9 in a sample obtained from the subject is between about 70 pg/ml and 550 pg/ml.

### Claim 37 (depends on 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claim 1 or 3 to 17 or 19 to 31, wherein the serum level of CXCL10 in a sample obtained from the subject is between about 300 pg/ml and 900 pg/ml.

### Claim 38

A method of treating multiple myeloma in a subject, the method comprising selecting a subject who has high serum levels of one or more of the following factors relative to control serum levels: hepatocyte growth factor (HGF), macrophage inhibitory factor (MIF), CCL27, G-CSF, CXCL9, and CXCL10; and administering to the subject an anti-KMA antibody.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the serum level of HGF in a sample obtained from the subject is above about 0.5 ng/ml.

### Claim 40 (depends on 38)

The method according to claim 38, wherein the serum level of MIF in a sample obtained from the subject is above about 5000 pg/ml.

### Claim 41 (depends on 38)

The method according to claim 38, wherein the serum level of CCL27 in a sample obtained from the subject is above about 500 pg/ml.

### Claim 42 (depends on 38)

The method according to claim 38, wherein the serum level of G-CSF in a sample obtained from the subject is above about 55 pg/ml.

### Claim 43 (depends on 38)

The method according to claim 38, wherein the serum level of CXCL9 in a sample obtained from the subject is above about 550 pg/ml.

### Claim 44 (depends on 38)

The method according to claim 38, wherein the serum level of CXCL10 in a sample obtained from the subject is above about 850 pg/ml.

### Claim 45 (depends on 38, 39, 40, 41, 42, 43, 44)

The method according to any one of claims 38 to 44, further comprising administering a proteasome inhibitor.

### Claim 46 (depends on 45)

The method according to claim 45, wherein the proteasome inhibitor is selected from the group consisting of marizomib, oprozomib, epoxomicin, salinosporamide A, carfilzomib, ixazomib and bortezomib.

### Claim 47 (depends on 46)

The method of claim 46, wherein the proteasome inhibitor is bortezomib.

### Claim 48

Use of a proteasome inhibitor and an anti-KMA antibody defined by any one of the preceding claims in the manufacture of a medicament for the treatment of multiple myeloma.

### Claim 49

A proteasome inhibitor and an anti-KMA antibody defined by any one of the preceding claims for use in the treatment of multiple myeloma.
